These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 33512688)

  • 1. Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis.
    Bonora BM; Avogaro A; Fadini GP
    J Endocrinol Invest; 2021 Jul; 44(7):1379-1386. PubMed ID: 33512688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis.
    Pal R; Banerjee M; Mukherjee S; Bhogal RS; Kaur A; Bhadada SK
    Ther Adv Endocrinol Metab; 2021; 12():2042018821996482. PubMed ID: 33680425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19.
    Rhee SY; Lee J; Nam H; Kyoung DS; Shin DW; Kim DJ
    Diabetes Metab J; 2021 Mar; 45(2):251-259. PubMed ID: 33752274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19.
    Zhou JH; Wu B; Wang WX; Lei F; Cheng X; Qin JJ; Cai JJ; Zhang XJ; Zhou F; Liu YM; Li HM; Zhu LH; She ZG; Zhang X; Yang J; Li HL
    World J Clin Cases; 2020 Nov; 8(22):5576-5588. PubMed ID: 33344548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong.
    Wong CKH; Lui DTW; Lui AYC; Kwok ACY; Low MCH; Lau KTK; Au ICH; Xiong X; Chung MSH; Lau EHY; Cowling BJ
    Diabetes Metab; 2022 Jan; 48(1):101307. PubMed ID: 34863934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies.
    Patoulias D; Doumas M
    Endocrinol Metab (Seoul); 2021 Aug; 36(4):904-908. PubMed ID: 34311543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
    Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
    Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?
    Krejner-Bienias A; Grzela K; Grzela T
    Arch Immunol Ther Exp (Warsz); 2021 Feb; 69(1):1. PubMed ID: 33527308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.
    Rakhmat II; Kusmala YY; Handayani DR; Juliastuti H; Nawangsih EN; Wibowo A; Lim MA; Pranata R
    Diabetes Metab Syndr; 2021; 15(3):777-782. PubMed ID: 33838614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of cohort studies.
    Charoenngam N; Rittiphairoj T; Ponvilawan B; Ungprasert P
    Diabetes Metab Syndr; 2021; 15(1):249-255. PubMed ID: 33465685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
    Bassendine MF; Bridge SH; McCaughan GW; Gorrell MD
    J Diabetes; 2020 Sep; 12(9):649-658. PubMed ID: 32394639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis.
    Chen Y; Lv X; Lin S; Arshad M; Dai M
    Front Endocrinol (Lausanne); 2022; 13():895458. PubMed ID: 35692410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients.
    Du H; Wang DW; Chen C
    J Cell Mol Med; 2020 Sep; 24(18):10274-10278. PubMed ID: 32713161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 - A systematic review and meta-analysis.
    Zein AFMZ; Raffaello WM
    Prim Care Diabetes; 2022 Feb; 16(1):162-167. PubMed ID: 34952805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is DPP4 inhibition a comrade or adversary in COVID-19 infection.
    Dalan R
    Diabetes Res Clin Pract; 2020 Jun; 164():108216. PubMed ID: 32416120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
    Liu X; Men P; Wang Y; Zhai S; Liu G
    Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
    Dombrowski S; Kostev K; Jacob L
    Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.